Circulating Tumour DNA and Its Prognostic Role in Management of Muscle Invasive Bladder Cancer: A Narrative Review of the Literature

Current management of non-metastatic muscle invasive bladder cancer (MIBC) includes radical cystectomy and cisplatin-based neoadjuvant chemotherapy (NAC), offers a 5-year survival rate of approximately 50% and is associated with significant toxicities. A growing body of evidence supports the role of...

Full description

Saved in:
Bibliographic Details
Published inBiomedicines Vol. 12; no. 4; p. 921
Main Authors Kapriniotis, Konstantinos, Tzelves, Lazaros, Lazarou, Lazaros, Mitsogianni, Maria, Mitsogiannis, Iraklis
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.04.2024
Subjects
Acids
Biomarkers
Biopsy
Bladder cancer
Cancer
Cancer therapies
Chemotherapy
circulating tumour deoxyribonucleic acid (DNA)
Cisplatin
ctDNA
Development and progression
Disease
Diseases
DNA
Immunotherapy
Invasiveness
liquid biopsies
Literature reviews
Medical prognosis
Metastases
Metastasis
muscle invasive bladder cancer (MIBC)
Mutation
Patients
Prognosis
Relapse
Survival
Tumors
Urological surgery
muscle invasive bladder cancer (MIBC)
liquid biopsies
bladder cancer
ctDNA
circulating tumour deoxyribonucleic acid (DNA)
Online AccessGet full text

Cover

More Information
Summary:Current management of non-metastatic muscle invasive bladder cancer (MIBC) includes radical cystectomy and cisplatin-based neoadjuvant chemotherapy (NAC), offers a 5-year survival rate of approximately 50% and is associated with significant toxicities. A growing body of evidence supports the role of liquid biopsies including circulating tumour DNA (ctDNA) as a prognostic and predictive marker that could stratify patients according to individualised risk of progression/recurrence. Detectable ctDNA levels prior to radical cystectomy have been shown to be correlated with higher risk of recurrence and worse overall prognosis after cystectomy. In addition, ctDNA status after NAC/neoadjuvant immunotherapy is predictive of the pathological response to these treatments, with persistently detectable ctDNA being associated with residual bladder tumour at cystectomy. Finally, detectable ctDNA levels post-cystectomy have been associated with disease relapse and worse disease-free (DFS) and overall survival (OS) and might identify a population with survival benefit from adjuvant immunotherapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines12040921